Research ArticleOriginal Article
Open Access

Impact of empirical oseltamivir discontinuation in hospitalized patients with community-acquired pneumonia after confirmed negative for influenza

Ashjan F. Alghanem, Fahad A. Aldhahri and Abdullah U. Althemery
Saudi Medical Journal October 2021, 42 (10) 1072-1077; DOI: https://doi.org/10.15537/smj.2021.42.10.20210324

References

  1. 1.↵
    1. Ghebrehewet S,
    2. MacPherson P,
    3. Ho A. Influenza
    . BMJ 2016; 355: i6258.
    OpenUrlFREE Full Text
  2. 2.↵
    1. Moscona A.
    Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353: 1363–1373.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    World Health Organization. [cited 2020 June 5]. Available from: https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).
  4. 4.↵
    1. Molinari NAM,
    2. Ortega-Sanchez IR,
    3. Messonnier ML,
    4. Thompson WW,
    5. Wortley PM,
    6. Weintraub E, et al.
    The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine 2007; 25: 5086–5096.
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.
    1. Thompson WW,
    2. Shay DK,
    3. Weintraub E,
    4. Brammer L,
    5. Bridges CB,
    6. Cox NJ, et al.
    Influenza-associated hospitalizations in the United States. JAMA 2004; 292: 1333–1340.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    Centers for Disease Control and Prevention (CDC. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR 2010; 59: 1057–1062.
    OpenUrlPubMed
  7. 7.↵
    1. Jefferson T,
    2. Jones MA,
    3. Doshi P,
    4. Del Mar CB,
    5. Hama R,
    6. Thompson MJ, et al.
    Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews 2014; 2014: CD008965.
  8. 8.
    1. Dobson J,
    2. Whitley RJ,
    3. Pocock S,
    4. Monto AS.
    Oseltamivir treatment for influenza in adults: A meta-analysis of randomized controlled trials. Lancet 2015; 385: 1729–1737.
    OpenUrlCrossRefPubMed
  9. 9.
    1. Treanor JJ,
    2. Hayden FG,
    3. Vrooman PS,
    4. Barbarash R,
    5. Bettis R,
    6. Riff D, et al.
    Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016–1024.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    1. Jefferson T,
    2. Jones M,
    3. Doshi P,
    4. Del Mar C.
    Neuraminidase inhibitors for preventing and treating influenza in healthy adults: Systematic review and meta-analysis. BMJ 2009; 339: b5106.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Muthuri SG,
    2. Venkatesan S,
    3. Myles PR,
    4. Leonardi-Bee J,
    5. Al Khuwaitir TSA,
    6. Al Mamun A, et al.
    Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: A meta-analysis of individual participant data. Lancet 2014; 2: 395–404.
    OpenUrl
  12. 12.↵
    1. Klarin I,
    2. Wimo A,
    3. Fastbom J.
    The association of inappropriate drug use with hospitalisation and mortality: A population-based study of the very old. Drugs Aging 2005; 22: 69–82.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Hussain M,
    2. Galvin HD,
    3. Haw TY,
    4. Nutsford AN,
    5. Husain M.
    Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resist 2017; 10: 121.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Fishman N.
    Antimicrobial stewardship. Am J Infect Control 2006; 34 Supplement 1: S55–S63.
    OpenUrl
  15. 15.↵
    Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. Atlanta: USA; 2014. p. 1729–1737.
  16. 16.↵
    1. Masterton RG.
    Antibiotic de-escalation. Crit Care Clin 2011; 27: 149–162.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. D’Hoore W,
    2. Bouckaert A,
    3. Tilquin C.
    Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol 1996; 49: 1429–1433.
    OpenUrlCrossRefPubMedWeb of Science
  18. 18.↵
    1. Faul F,
    2. Erdfelder E,
    3. Lang AG,
    4. Buchner A.
    G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007; 39: 175–191.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Kulesa A,
    2. Krzywinski M,
    3. Blainey P,
    4. Altman N.
    Sampling distributions and the bootstrap. Nat Methods 2015; 12: 477–478.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Barlam TF,
    2. Cosgrove SE,
    3. Abbo LM,
    4. Macdougall C,
    5. Schuetz AN,
    6. Septimus EJ, et al.
    Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016; 62: e51–e77.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Pettit NN,
    2. Matushek S,
    3. Charnot-Katsikas A,
    4. Tesic V,
    5. Boonlayangoor S,
    6. Brielmaier B, et al.
    Comparison of turnaround time and time to oseltamivir discontinuation between two respiratory viral panel testing methodologies. J Med Microbiol 2015; 64: 312–313.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Bohan JG,
    2. Remington R,
    3. Jones M,
    4. Samore M,
    5. Madaras-Kelly K.
    Outcomes associated with antimicrobial de-escalation of treatment for pneumonia within the veterans healthcare administration. Open Forum Infect Dis 2017; 4: ofw244.
    OpenUrl
  23. 23.↵
    1. Tabah A,
    2. Cotta MO,
    3. Garnacho-Montero J,
    4. Schouten J,
    5. Roberts JA,
    6. Lipman J, et al.
    A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial De-escalation in the Intensive Care Unit. Clin Infect Dis 2016; 62: 1009–1017.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Jones JA,
    2. Reeve CA.
    Factors influencing the use of clinical guidelines by general practitioners working in a setting of complex multimorbidity: A case study by interviews. BMC Fam Pract 2018; 19: 157.
    OpenUrl
  25. 25.↵
    1. Uyeki TM.
    Influenza diagnosis and treatment in children: A review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J 2003; 22: 164–177.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    1. Uyeki TM,
    2. Bernstein HH,
    3. Bradley JS,
    4. Englund JA,
    5. File TM, Jr.,
    6. Fry AM, et al.
    Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis 2019; 68: e1–e47.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords